Prenatal diagnosis of 4953 pregnant women with indications for genetic amniocentesis in Northeast China

Rulin Dai, Yang Yu, Qi Xi, Xiaonan Hu, Haibo Zhu, Ruizhi Liu and Ruixue Wang*

Abstract

Background: Several different technologies are used for prenatal screening procedures and genetic diagnostic technologies. We aimed to investigate the rates of chromosomal abnormalities in cases with different abnormal prenatal indications and to determine the relationships between fetal chromosomal abnormalities and indicators of prenatal abnormalities in Northeast China.

Methods: We evaluated 4953 16- to 23-week singleton gestation cases using amniocentesis and a total of 3583 participants received serological screening. Fetal chromosomal analyses were performed for all samples using fluorescence in situ hybridization and karyotyping.

Results: Among these samples, 204 (4.12%) had fetal chromosomal abnormalities. A total of 3583 participants received serological screening, among whom 102 (2.85%) exhibited positive results. A total of 309 participants had ultrasonography; 42 (13.6%) of these had abnormalities. Among 97 participants who had non-invasive prenatal testing (NIPT), 59 (61%) had positive results. Among 1265 participants with advanced maternal age, 78 (6.2%) had abnormal results.

Conclusion: The serological screening and NIPT that were included in the prenatal screening methods all had false positive and false negative rates. Although they are both prenatal screening techniques, maternal serum screening cannot be replaced by NIPT. The pregnancy women should accept NIPT in a qualified prenatal diagnostic center. We recommend that pregnant women at high or critical risk undergoing prenatal screening should confirm the fetal karyotype through amniocentesis. Moreover, if women receive a positive result via NIPT, they should not have a pregnancy termination without undergoing further prenatal diagnosis.

Keywords: Prenatal diagnosis, Advanced maternal age (AMA), Non-invasive prenatal testing (NIPT), Ultrasonography, Fluorescence in situ hybridization (FISH)

Introduction

Several different technologies are used for prenatal genetic screening procedures and diagnostic technology, including ultrasonography, the double-marker test, the triple marker test, non-invasive prenatal testing (NIPT) [1]. Invasive prenatal diagnostic techniques are feasible tools for confirming fetal chromosomal abnormalities [2]. Amniocentesis is a reliable and low-risk method of achieving suitable genetic material [3]. Application of this technique to amniotic fluid analysis can enable physicians to recognize fetal genetic abnormalities. Routine chromosome analysis has been the gold standard for prenatal cytogenetic diagnosis [4]. However, karyotyping has a limitation in that embryonic cell culture takes about 2 weeks or even longer. These long waiting times for karyotyping results can cause much psychological distress to the couples.

At present, fluorescence in situ hybridization (FISH) has been used for rapid prenatal diagnosis of the most common aneuploidies in pregnant woman at high risk. Down’s syndrome (DS, trisomy 21) and Edwards syndrome (ES, trisomy 18) are two most prevalent autosomal trisomies...
encountered at birth. The main advantages of FISH technology are that it is rapid and reliable [5, 6].

Non-invasive analysis of fetal genetic traits using material blood samples has been commonly used for the prenatal diagnosis of DS [7]. Lo et al. [8] first reported the presence of fetal DNA in maternal blood. Then, NIPT was initially conducted by DNA sequencing techniques [9, 10]. Many physicians dealing with high-risk pregnant women consider this to be one of the safest methods in the detection of fetal aneuploidies [11].

Nuchal translucency (NT) testing in combination with measurements of pregnancy-associated plasma protein A and the free β subunit of human chorionic gonadotropin (hCG) have been included in prenatal screening options during the first trimester. In the second trimester, serum monitoring using triple screening (free β-hCG, maternal serum alpha fetoprotein (AFP), and unconjugated estradiol levels) or quadruple screening (hCG, inhibin A, maternal serum AFP, and unconjugated estradiol levels), and ultrasonography have been included [12, 13].

Ultrasonography is generally considered to be a safe method of imaging, often used for diagnosing fetal congenital disabilities or abnormal development. Thus, observing fetal NT values and nose bone development could allow a prediction of the possibility of the fetus having DS. However, this technology has a high false positive rate of 5% [14]. In addition to detecting DS, an increased NT have been described in association with other genetic fetal syndromes like 22q11 microdeletion syndrome, Noonan syndrome, Smith-Lemli-Opitz syndrome, multiple pterygium syndrome (Escobar syndrome), Fanconi pancytopenia syndrome etc. [15–21].

Here we aimed to investigate the rates of chromosomal abnormalities in various abnormal prenatal conditions, and to determine the relationship between these and indicators of prenatal abnormalities in Northeast China.

### Results

All 4953 amniocentesis samples except for one (karyotyping showed trisomy 18; the FISH result was normal) were the same by FISH and karyotyping. Among the samples, 204/4952 (4.12%) had fetal chromosomal abnormalities. A total of 3583 participants received serological screening, among which 102 (2.85%) exhibited positive results. A total of 309 participants underwent ultrasonography and 42 (13.6%) had abnormalities. Among 97 participants who had NIPT, 59 (61%) had positive results. Of 1265 participants classed as women of AMA, 78 (6.17%) had abnormal results.

Many indicators in our study could reflect abnormal fetal development, such as positive serological and NIPT results, women of AMA, abnormal ultrasound findings and a history of abnormal pregnancies. The most frequent related indicator was a positive serological finding (102/204; 50%), followed by women of AMA (78/204; 38.2%), a positive NIPT (59/204; 28.9%) and abnormal ultrasound findings (42/204; 20.6%; Table 1).

Among 204 abnormal samples, the most frequent karyotype was trisomy 21 (143/204; 70.1%), followed by trisomy 18 (33/204; 16.2%; Table 2, Fig. 1). Of the 204 abnormal fetal karyotypes, 97 (47.6%) had a positive NIPT. The true positive fetal karyotype by NIPT was 61% (59/97), however, the false positive rate was 39% (38/97). Trisomy 21 had the highest true positive rate by NIPT (47%, 46/97), however, this also had a higher false positive rate (19%, 18/97, Table 3).

Of the 102 positive serological samples, there were 20 cases with a positive NIPT result. Among these samples, 82 high-risk samples (incidence of DS ≥ 1:270 and of ES ≥ 1:350) had abnormalities, 20 reaching the critical point for high-risk samples (incidence of DS 1:270–1:1000 and of ES 1:350–1:1000) had abnormalities (Table 4).

Ultrasonography is used in determining many types of fetal abnormalities. These include increased NT, heart

| Table 1 Maternal age and fetal chromosomal abnormality indicators |
|---------------------------------------------------------------|
| Abnormal indicators   | ≥40 | 35–39 | 30–34 | 25–29 | < 25 | Total, n |
| Positive serological | 7   | 9     | 22    | 32    | 11   | 81       |
| Positive NIPT         | 9   | 10    | 11    | 3     | 1    | 34       |
| Abnormal ultrasound   | 3   | 7     | 11    | 15    | 0    | 36       |
| Age factor            | 13  | 11    | 2     | 0     | 0    | 26       |
| History of abnormal pregnancy | 0   | 0     | 0     | 1     | 0    | 1        |
| Positive NIPT+        | 3   | 4     | 2     | 7     | 4    | 20       |
| Positive serological  | 1   | 0     | 0     | 3     | 1    | 5        |
| Positive NIPT+        | 0   | 1     | 0     | 0     | 0    | 1        |
| Abnormal ultrasound+  | 36  | 42    | 48    | 61    | 17   | 204      |

Dai et al. Molecular Cytogenetics (2019) 12:45 Page 2 of 7
abnormalities, choroid plexus cysts, lymphatic hydroceles of the neck, skeletal and brain abnormalities, increased neck fold (NF), and kidney, bowel, and lung abnormalities. Ultrasonic findings of increased NT or NF values, and of skeletal or bowel abnormalities might indicate DS, followed by heart abnormalities (Table 5).

Discussion

At present, several different technologies are used for prenatal screening and diagnosis. Here we aimed to determine the relationships between fetal chromosomal abnormalities and prenatal indicators of fetal abnormalities in Northeast China.

The amniocenteses were for indications including AMA, a positive NIPT result, a positive aneuploidy screening result, abnormal ultrasound findings, a history of abnormal pregnancy, and paternal/maternal carriers of known genetic disorders. Among the samples, 204 (4.12%) had fetal chromosomal abnormalities. Among these, the most frequent indicators were a positive serological finding of possible abnormalities, followed by AMA, a positive NIPT and abnormal ultrasound observations.

The serological screening is the method determining a risk of fetal chromosomal disease. Recent studies have suggested that serological screening is an important marker related to fetal chromosomal aneuploidy, a single abnormal serum marker with ultrasound examination can facilitate screening for fetal chromosome abnormalities in pregnant women [22], and could increased the detection rate of fetal chromosomal aneuploidy through serological screening [23]. High-risk and critical-risk pregnant women subjected to prenatal screening in the first and second trimesters of pregnancy should undergo prenatal diagnosis. In the present study, among 102 positive serological samples, 20 that reached the critical point for risk had abnormalities. Therefore, we recommend that critical point for risk pregnant women should confirm fetal karyotypes by amniocentesis, which is often overlooked by people. The elderly pregnant women, who were at critical-risk and refused amniocentesis, underwent NIPT of fetal DNA upon recommendation. Although both are prenatal screening techniques, serological screening cannot be replaced by NIPT.

In our study, the most frequent abnormal karyotype was of DS (70.1%), followed by ES (16.2%). Non-invasive analysis of fetal genetic traits using material blood samples has been used commonly for the prenatal diagnosis of DS. However, we found true positive rate of NIPT for diagnosing fetal karyotypes was 60.82%, false positive rate was 39.18%. Trisomy 21 (DS) had the highest true positive rate by NIPT (47.42%); however, it also had a higher false positive rate (18.56%), followed by the false positive rate of sex chromosome abnormalities (8.25%). This is inconsistent with results published previously. Zhang et al. [24] reported that the accuracy and specificity of screening for DS in 87 women classed as being of AMA was 100%. Due to NIPT is rather newly introduced, and experiences with discordant results are few. Although NIPT is not done by our laboratory, clinical informations were directly obtained from pregnant women.

Table 2 Maternal age and karyotype of fetal chromosomal abnormality

| Fetal chromosomal karyotype | Cases, n | ≧40 | 35–39 | 30–34 | 25–29 | <25 |
|-----------------------------|----------|-----|-------|-------|-------|-----|
| Trisomy 21                  | 143       | 26  | 31    | 37    | 36    | 13  |
| Trisomy 18                  | 33        | 9   | 5     | 3     | 14    | 2   |
| XXX                         | 10        | 0   | 2     | 3     | 5     | 0   |
| Trisomy 13                  | 6         | 1   | 2     | 0     | 2     | 1   |
| Monosomy X                  | 5         | 0   | 0     | 3     | 2     | 0   |
| Sex chromosome mosaicism    | 3         | 0   | 0     | 1     | 1     | 1   |
| XYY                         | 2         | 0   | 2     | 0     | 0     | 0   |
| XXY                         | 2         | 0   | 0     | 1     | 1     | 0   |
| Total                       | 204       | 36  | 42    | 48    | 61    | 17  |

Fig. 1 FISH results of the most common fetal chromosomal abnormalities. a Trisomy 21, b Trisomy 18, c XXX, d Trisomy 13
using the questionnaire. Our FISH results confirm that the sensitivity of NIPT technology is not so high. In 1997, cell-free fetal DNA fragments were discovered in the plasma of pregnant women, and in 2011, NIPT was introduced into clinic and commerce [25]. In view of a high sensitivity and specificity of NIPT, it is considered as an incomparable screening test for fetal aneuploidy. However, in 2016, the American College of Medical Genetics and Genomics has released an important new policy statement that NIPS instead of NIPT, where the “S” represents screening, it should be highlighted that NIPT is not a diagnostic technique [11]. One should remember that the NIPT is only a screening test which provides a risk for the genetic disorder, but not the diagnosis. Many companies in the market can now do NIPT testing, and we recommend that pregnancy women should accept it in a qualified prenatal diagnostic center.

Some studies have discussed the effect of maternal age on spontaneous abortion and have suggested that AMA is an important factor related to fetal chromosomal aneuploidy, with aneuploidy rates increasing with age [26, 27]. We aimed to determine the relationship between abnormal fetal karyotype and AMA using amniocentesis. Therefore, we divided all samples with abnormal fetal karyotypes into five age groups according to maternal age. The fetal abnormality rate in 1265 women classed as AMA was 6.17%. Among abnormal fetal findings, AMA women accounted for 38.2%. We consider that physicians dealing with such AMA women should pay more attention to spontaneous abortion, as performing amniocentesis is still the best choice in the second trimester. Chromosome abnormalities usually result in developmental arrest and spontaneous abortion. Our laboratory historically [28] used FISH technology for testing chorionic villi, and found that the kinds of fetal abnormalities, numbers of abortions, and chromosomal abnormality rates increased with increasing maternal age, and we hypothesize whether the larger probability of chromosomal abnormalities is due to increased mutation rate with maternal age, or due to a worse in-utero conditions. FISH probes for abortion samples could detect more chromosomal numerical abnormalities for it can detect 16/22 additionally. Chromosomal abnormalities in aborted fetus can more accurately reflect the fetal chromosomal anomalies in AMA women.

Ultrasoundography is generally considered a safe and indispensable method of imaging in pregnancy, although it cannot detect genetic defects. More than 50 genetic conditions have been described in association with an increased NT [29, 30]. Pregnant woman with a fetal NT of > 3.0 mm indicating DS are deemed as having an abnormal pregnancy and these were the most frequent in our study. Other abnormal ultrasonic results included heart abnormalities, choroid plexus cysts, lymphatic hydroceles in the neck, and skeletal abnormalities. Among the 18 increased NT pregnant women, 12 patients (67%) had Trisomy 21. Compared to normal fetuses of the same gestational age, the majority of fetuses with DS have an increased NT measurement [31]. Furthermore, increased NT is attributed to aortic isthmus narrowing, cardiovascular defects which cause overperfusion of the head and neck, or abnormal/delayed development of the lymphatic system [32]. Some studies have found 36% of DS had congenital malformations. Cardiac defects were the most common malformation [33]. But considering the sample size is small, the relationship cannot be confirmed confidently, thus the studies need further research include a greater number of patients.

### Conclusion

We found that the rate of fetal chromosomal abnormalities was 4.12% through amniocentesis. The serological screening and NIPT that were included in the prenatal screening methods all had false positive and false negative rates. Although they are both prenatal screening techniques, maternal serum screening cannot be replaced by NIPT. The pregnancy women should accept NIPT in a qualified prenatal diagnostic center. We recommend that pregnant women at high or critical risk undergoing prenatal screening should confirm the fetal karyotype through amniocentesis. Moreover, if women receive a positive result via NIPT, they should not have a pregnancy termination without undergoing further prenatal diagnosis.

| Table 3 | Fetal positive karyotype analysis of NIPT |
|---------|----------------------------------------|
| Fetal karyotype | False positive, n(%) | True positive, n(%) |
| Trisomy 21 | 18(18.56%) | 46(47.42%) |
| Trisomy 18 | 6(6.19%) | 8(8.25%) |
| Trisomy 13 | 2(2.06%) | 1(1.03%) |
| Sex chromosome abnormal | 8(8.25%) | 4(4.12%) |
| Other chromosome abnormal | 4(4.12%) | 0(0.00) |
| Total | 38(39.18%) | 59(60.82%) |

| Table 4 | Positive serological and positive NIPT |
|---------|----------------------------------------|
| Cases, n | DS ≥ 1:270 & ES ≥ 1:350, n | DS 1:270~1:500 & ES 1:350~1:500, n | DS and ES 1:500~1:1000, n |
| Positive serological | 102 | 82 | 16 | 4 |
| Positive NIPT | 20 | 14 | 4 | 2 |
Materials and methods

Sample collection

We evaluated 4953 16- to 23-week singleton gestation cases for amniocentesis, who attended the outpatient abortion clinic of the Prenatal Diagnosis departments of the First Hospital of Changchun, Jilin Province, Northeastern China, between November 14, 2012 and December 12, 2018. This study was approved by the ethics committee of the hospital (No.2012-115), and all patients provided informed consent to participate in the study.

The amniocenteses were for indications including advanced AMA, a positive NIPT result, a positive aneuploidy screening result, abnormal ultrasound, history of abnormal pregnancy, and paternal/maternal carriers. We enrolled 4952 samples out of 4953 amniocentesis samples except for one karyotyping showed trisomy 18, however the FISH result was normal. Because some pregnant women involved two or more indications, the 4952 participants contained 5254 indications. Clinical information was mostly obtained from their clinicians using a questionnaire. A total of 3583 participants received serological screening, 97 had NIPT, 309 had ultrasonography and 1265 participants were classed as AMA. To analyze the possible relationship between maternal age and abnormal embryo development, we further divided the women providing samples into five age groups (< 25, 25–29, 30–34, 35–39, and ≥ 40 years).

Karyotype analysis of amniotic fluid cells

Amniotic fluid cells were obtained by amniocentesis at 16–23 weeks of gestation. They were cultured in CHANG Amnio® Medium (Irvine Scientific, Santa Ana, CA, USA), followed by treatment with colcemid. A total of 4953 amniocentesis samples were processed. G-banding of metaphase chromosomes was performed by standard methods [34]. For each individual, a minimum of 30 metaphase cells was counted and at least five cells were analyzed. Chromosome abnormalities were described according to the criteria established by the International System for Human Cytogenetic Nomenclature [34].

FISH analysis

FISH was performed using commercially available whole-chromosome painting probes for chromosomes 13, 18, 21, X and Y. FISH was carried out using centromeric probes for chromosomes 18, X and Y (CSP18-Spectrum blue, CSPX-Spectrum green and CSPY-Spectrum red, Beijing GP Medical Technologies, Beijing, P. R. China). The chromosome 13- and 21-specific probes (GLP13- Spectrum green and GLP21-Spectrum red, respectively; Beijing GP Medical Technologies) were used. Chromosome denaturation, hybridization, and signal detection were done as described by Luo et al. [35].

NIPT analysis

With the continually evolving of next-generation sequencing technologies, NIPT also has been applied in several sequencing platforms such as a semiconductor sequencing platform [36, 37], Illumina sequencing platform [37, 38], and the Beijing Genomics Institute (BGI) sequencing platform [39]. Maternal peripheral blood was collected in blood collection tubes and processed within the required time. Student’s t test was performed based on null/alternative hypotheses, and the relative logarithmic likelihood odds ratio was subsequently calculated. Absolute z-score > 3 and L score > 1 were used as warning criteria [40–42].

Prenatal serological screening analysis

The first-trimester combined screening (FTS) was performed at 11–13+6 weeks of gestation using maternal age, fetal NT thickness and concentrations of maternal serum free β-hCG and pregnancy-associated plasma protein-A (PAPP-A) for risk calculation. The second-trimester triple screening (STS) was performed at 15–20+6 weeks of gestation using maternal age and maternal serum concentrations of AFP, free β-hCG and unconjugated estriol (uE3)

Table 5 Ultrasonic findings of abnormal fetal

| Ultrasonography          | Cases, n | Trisomy 21 | Trisomy 18 | Trisomy 13 | Monosomy X | XXX |
|--------------------------|----------|------------|------------|------------|------------|-----|
| Increased NT             | 18       | 12         | 2          | 0          | 2          | 2   |
| Heart abnormality        | 14       | 4          | 5          | 2          | 2          | 1   |
| Choroid plexus cyst      | 6        | 0          | 6          | 0          | 0          | 0   |
| Neck lymphatic hydrocele | 6        | 1          | 1          | 0          | 3          | 1   |
| Bone abnormality         | 6        | 4          | 1          | 1          | 0          | 0   |
| Brain abnormality        | 5        | 1          | 2          | 2          | 0          | 0   |
| Increased NF             | 4        | 3          | 0          | 0          | 0          | 1   |
| Kidney abnormality       | 4        | 1          | 1          | 2          | 0          | 0   |
| Bowel abnormality        | 2        | 2          | 0          | 0          | 0          | 0   |
| Lung abnormality         | 2        | 1          | 0          | 0          | 0          | 1   |

Dai et al. Molecular Cytogenetics (2019) 12:45 Page 5 of 7
for risk calculation. Gestational age was determined by fetal crown rump length (CRL) or biparietal diameter (BPD). In all cases, maternal serum was sampled at 11–13+6 or 15–20+6 weeks of gestation after obtaining informed written consent. The ultrasound examination and the maternal blood extraction for FTS were performed on the same day. The serum marker levels of FTS and STS were measured by AutoDELFIA (PerkinElmer, Finland). Both marker levels and NT thickness were converted into multiple of the median (MoM), which is used to calculate the risk of chromosomal abnormality, base on gestational age. As well as information on earlier pregnancy with DS, maternal weight, maternal age and smoking habits were taken into account for risk calculation on DS. DS screen-positive at a term risk cut-off of 1 in 270 for both first and second trimester tests, and ES risk rate < 1/350.

Abbreviations
ACMG: American College of Medical Genetics and Genomics; AFP: Alpha fetoprotein; AAM: Advanced maternal age; BPD: Biparietal diameter; CRL: Crown rump length; DS: Down’s syndrome; ED: Edwards syndrome; FISH: Fluorescence in situ hybridization; FTS: First-trimester combined screening; HCG: Human chorionic gonadotropin; NF: Neck fold; NIPS: Non-invasive Prenatal Screening; NIPT: Non-invasive prenatal testing; NT: Nuchal translucency; PAPP-A: Pregnancy-associated plasma protein-A; STS: Second-trimester triple screening; uE3: Unconjugated estradiol

Acknowledgements
Not applicable.

Authors’ contributions
RD drafted the manuscript. YY and QX performed the statistical analyses. RD, XH and HZ participated in data analysis. RD, RL and RW conceived of the study and participated in the design and coordination of the study. All authors read and approved the final manuscript.

Funding
This work was kindly supported by the “Thirteenth Five-Year” Science and Technology Program of Jilin Provincial Education department (JJKH2018B0095K).

Availability of data and materials
The data used to support the findings of this study are included within the article.

Ethics approval and consent to participate
The study was approved by the ethics committee of First Hospital (No.2012–115), and all patients provided informed consent to participate in the study. All subjects provided written informed consent prior to participation.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 6 July 2019 Accepted: 18 October 2019
Published online: 06 November 2019

References
1. Sheeh F, Rahman M, Liehr T, Desai M, Patel B, Modi C, et al. Prenatal screening of cytogenetic abnormalities—a Western Indian experience. BMC Pregnancy Childbirth. 2015;15:90.
2. Zhang L, Zhang XH, Liang MY, Ren MH. Prenatal cytogenetic diagnosis study of 2782 cases of high-risk pregnant women. Chin Med J (Engl). 2010;123(4):423–30.
3. Grether-González P, Cámara-Polanco V, Ullaós-Avilés V, Salas-Labadia C, Almanza-Márquez R, Kogan-Frenk S, et al. Prenatal diagnosis by amniocentesis. Clinical and cyto genetic experience in 1,500 cases. Ginecol Obstet Mex. 2010;78(8):493–303.
4. Wilson RD, Blight G, Langlois S. Diagnosing chromosomal abnormalities from “big” to “small” with molecular cytogenetic technology. J Obstet Gynaecol Can. 2003;31(5):414–21.
5. Mann K, Donaghue C, Fox SP, Docherty Z, Ogilvie CM. Strategies for the rapid prenatal diagnosis of chromosome aneuploidy. Eur J Hum Genet. 2004;12(11):1907–15.
6. Ja CW, Wang SY, Ma YM, Lan YL, Si YM, Yu L, et al. Fluorescence in situ hybridization in uncultured amniocytes for detection of aneuploidy in 421 prenatal cases. Chin Med J. 2011;124(8):1164–8.
7. Lo YMD, Chiu RWK, Chan KCA, Chung GTY. Free fetal DNA in maternal circulation. JAMA. 2004;292(23):2835–6.
8. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485–7.
9. Lo YM, Tsai NB, Chiu RW, Lau TK, Leung TN, Heung MM, et al. Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. Nat Med. 2007;13(2):218–23.
10. Chiu RW, Cantor CR, Lo YM. Non-invasive prenatal diagnosis by single molecule counting technologies. Trends Genet. 2009;25(7):324–31.
11. Gregg AR, Skatko BG, Benkendorf JL, Monaghan KG, Bajaj K, Best RS, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2016;18(10):1056–65.
12. Wald NJ, Cuuckle HS, Densern JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down’s syndrome in early pregnancy. BMJ. 1998;297(6653):883–7.
13. Shaw SW, Lin SY, Lin CH, Su YN, Cheng PJ, Lee CN, et al. Second-trimester maternal serum quadruplet test for Down syndrome screening: a Taiwanese population-based study. Taiwan J Obstet Gynecol. 2010;49(1):30–4.
14. Muller F, Benattar C, Audibert F, Roussel N, Dreuux S, Cuuckle H. First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical. Prenat Diagn. 2003;23(10):833–6.
15. Mangione R, Guyon F, Taine L, Wien ZQ, Roux D, Verdua A, et al. Pregnancy outcome and prognosis in fetuses with increased first-trimester nuchal translucency. Fetal Diagn Ther. 2001;16(5):360–3.
16. Souka AP, Kampil E, Bakalis S, Heath V, Nicolaides KH. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol. 2001;18(1):19–7.
17. Senat MV, De Keersmaecker B, Audibert F, Montcharmont G, Frydman R, Ville Y. Pregnancy outcome in fetuses with increased nuchal translucency and normal karyotype. Prenat Diagn. 2002;22(11):907–9.
18. Bilardo CM, Müller MA, Pajkrt E, Clur SA, van Zalen MM, Blijis MA. Increased nuchal translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet Gynecol. 2007;30(1):11–8.
19. Mula R, Goncê A, Bennnár M, Arigita M, Nadal A, Sánchez A, Botet F, Borrell A, et al. Increased nuchal translucency and normal karyotype: prenatal and pediatric outcomes at 2 years of age. Ultrasound Obstet Gynecol. 2012;39(1):34–41.
20. Pergament E, Alamillo C, Sak K, Fidder M. Genetic assessment following increased nuchal translucency and normal karyotype. Prenat Diagn. 2011;31(3):307–10.
21. Grande M, Jansen FA, Blumenfeld YJ, Fisher A, Oddie BO, Haak MC, et al. Genomic microarray in fetuses with increased nuchal translucency and normal karyotype: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2015;46(6):650–8.
22. Liu L, Zhou P, Cao Z, Tan X. Middle pregnancy ultrasound screening for fetal chromosomal diseases. Mol Med Rep. 2017;16(3):7641–8.
23. Fang Y, Wang G, Wang C, Suo F, Gu M, Xia Y. The Diagnosis Pattern of Mid-Trimester Fetal Chromosomal Aneuploidy in Xuzhou and the Clinical Applications. Cell Biochem Biophys. 2015;73(2):267–70.
24. Zhang L, Zhang B. Second-generation non-invasive high-throughput DNA sequencing technology in the screening of Down’s syndrome in advanced maternal age women. Biomed Rep. 2016;4(6):715–8.
25. Hartwig TS, Ambye L, Sørensen S, Jørgensen FS. Discordant non-invasive prenatal testing (NIPT): a systematic review. Prenat Diagn. 2017;37(6):527–39.
26. Spandorfer SD, Davis OK, Bammat LI, Chung PH, Rosenwaks Z. Relationship between maternal age and aneuploidy in in vitro fertilization pregnancy loss. Fertil Steril. 2004;81(5):1265–9.

27. Foyouzi N, Cedars MI, Huddleston HG. Cost-effectiveness of cytogenetic evaluation of products of conception in the patient with a second pregnancy loss. Fertil Steril. 2012;98(1):151–5.

28. Dai R, Li L, Zhu H, Geng D, Deng S, Liu R. Effect of maternal age on spontaneous abortion during the first trimester in Northeast China. J Matern Fetal Neonatal Med. 2018;31(14):1824–9.

29. Zadeh N, Hudgins L, Norton ME. Nuchal translucency measurement in fetuses with spinal muscular atrophy. Prenat Diagn. 2011;31(4):327–30.

30. Barone C, Bianca S. Further evidence of no association between spinal muscular atrophy and increased nuchal translucency. Fetal Diagn Ther. 2013;33(1):65–8.

31. Shiela S, Amargandhi M, Bhupendra J, Moulali S, Kristine T. First trimester maternal serum screening using biochemical markers PAPP-A and free ß-hCG for Down syndrome, Patau syndrome and Edward syndrome. Indian J Clin Biochem. 2013;28(1):1–12.

32. von Kaisenberg CS, Nicolaides KH, Brand-Saberi B. Lymphatic vessel hypoplasia in fetuses with turner syndrome. Hum Reprod. 1999;14(3):823–6.

33. Gilboa Y. Second-trimester ultrasound for adjusting Patient’s risk for Down syndrome. Isr Med Assoc J. 2017;19(1):55–6.

34. Shaffer LG, Slovak ML, Campbell LJ. ISCN 2013: an international system for human cytogenetic nomenclature. Basel: S.Karger, 2013. p. 138.

35. Luo B, Li W, Deng CH, Zheng FF, Sun XZ, Wang DH, et al. Utility of fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma. Cancer Genet Cytogenet. 2009;189(2):93–7.

36. Jeon YJ, Zhou Y, Li Y, Guo Q, Chen J, Quan S, et al. The feasibility study of non-invasive fetal trisomy 18 and 21 detection with semiconductor sequencing platform. PLoS One. 2014;9(10):e110240.

37. Xue Y, Zhao G, Li H, Zhang Q, Lu J, Yu B, et al. Non-invasive prenatal testing to detect chromosome aneuploidies in 57,204 pregnancies. Mol Cytogenet. 2019;12:29.

38. Song Y, Liu C, Qi H, Zhang Y, Bian X, Liu J. Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population. Prenat Diagn. 2013;33(7):700–6.

39. Zhu FY, Chen MX, Ye NH, Qiao WM, Gao B, Law WK, et al. Comparative performance of the BGISeq-500 and Illumina HiSeq4000 sequencing platforms for transcriptome analysis in plants. Plant Methods. 2018;14:69.

40. Dan S, Wang W, Ren J, Li Y, Hu H, Xu Z, et al. Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11105 pregnancies with mixed risk factors. Prenat Diagn. 2012;32(13):1225–32.

41. Lau TK, Chan MK, Lo PS, Chan HY, Chan WS, Koo TY, et al. Clinical utility of noninvasive fetal trisomy (NIFTY) test—early experience. J Matern Fetal Neonatal Med. 2012;25(10):1856–9.

42. Chen S, Lau TK, Zhang C, Xu C, Xu Z, Hu P, et al. A method for noninvasive detection of fetal large deletions/ duplications by low coverage massively parallel sequencing. Prenat Diagn. 2013;33(6):584–90.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.